Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing

References

• Shelekhova KV. [Changes in the WHO classification of soft tissue tumors]. Arkh Patol. 2015;77:48–54. doi:10.17116/patol201577148.
   PubMedGoogle Scholar
• Kasper B, Strobel P, Hohenberger P. Desmoid tumors: clinical features and treatment options for advanced disease. Oncologist. 2011;16:682–93. doi:10.1634/theoncologist.2010-0281.
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, Dekkers OM, Hogendoorn PC, Vasen HF. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer. 2011;129:256–61. doi:10.1002/ijc.25664.
   PubMed Web of Science ®Google Scholar
• Seow-Choen F. The management of desmoids in patients with familial adenomatous polyposis (FAP). Acta Chir Iugosl. 2008;55:83–7. doi:10.2298/ACI0803083S.
   PubMedGoogle Scholar
• Merchant NB, Lewis JJ, Woodruff JM, Leung DH, Brennan MF. Extremity and trunk desmoid tumors: a multifactorial analysis of outcome. Cancer. 1999;86:2045–52. doi:10.1002/(SICI)1097-0142(19991115)86:10<2045::AID-CNCR23>3.0.CO;2-F.
   PubMed Web of Science ®Google Scholar
• Levy AD, Rimola J, Mehrotra AK, Sobin LH. From the archives of the AFIP: benign fibrous tumors and tumorlike lesions of the mesentery: radiologic-pathologic correlation. Radiographics: a review publication of the Radiological Society of North America, Inc 2006;26:245–64. doi:10.1148/rg.261055151.
   PubMed Web of Science ®Google Scholar
• Ballo MT, Zagars GK, Pollack A, Pisters PW, Pollack RA. Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J clin oncol: official journal of the American Society of Clinical Oncology. 1999;17:158–67. doi:10.1200/JCO.1999.17.1.158.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, Rust PF, Thomas CR, Turrisi AT. Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors – A comparative review of 22 articles. Cancer. 2000;88:1517–23. doi:10.1002/(SICI)1097-0142(20000401)88:7<1517::AID-CNCR3>3.0.CO;2-9.
   PubMed Web of Science ®Google Scholar
• Eastley N, McCulloch T, Esler C, Hennig I, Fairbairn J, Gronchi A, Ashford R. Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. Eur J Surg Oncol: the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2016;42:1071–83. doi:10.1016/j.ejso.2016.02.012.
   PubMed Web of Science ®Google Scholar
• van Broekhoven DL, Verhoef C, Grunhagen DJ, van Gorp JM, den Bakker MA, Hinrichs JW, de Voijs CM, van Dalen T. Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis. Ann Surg Oncol. 2015;22:1464–70. doi:10.1245/s10434-014-4156-x.
   PubMed Web of Science ®Google Scholar
• Lips DJ, Barker N, Clevers H, Hennipman A. The role of APC and beta-catenin in the aetiology of aggressive fibromatosis (desmoid tumors). Ejso-Eur J Surg Onc. 2009;35:3–10. doi:10.1016/j.ejso.2008.07.003.
   PubMed Web of Science ®Google Scholar
• Tejpar S, Nollet F, Li C, Wunder JS, Michils G, dal Cin P, Van Cutsem E, Bapat B, van Roy F, Cassiman JJ, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999;18:6615–20. doi:10.1038/sj.onc.1203041.
   PubMed Web of Science ®Google Scholar
• Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H, Alman BA. beta-Catenin stabilization dysregulates mesenchymal cell proliferation, motility, and invasiveness and causes aggressive fibromatosis and hyperplastic cutaneous wounds. Proc Nati Acad Sci U S A. 2002;99:6973–8. doi:10.1073/pnas.102657399.
   PubMed Web of Science ®Google Scholar
• Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, et al. Cyclooxygenase-2 and platelet-derived growth factor receptors as potential targets in treating aggressive fibromatosis. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2007;13:5034–40. doi:10.1158/1078-0432.CCR-07-0336.
   PubMed Web of Science ®Google Scholar
• Schonthal AH. Antitumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2: implications for glioma therapy. Neurosurg Focus. 2006;20:E21. doi:10.3171/foc.2006.20.4.14.
   PubMedGoogle Scholar
• Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett. 2013;332:313–24. doi:10.1016/j.canlet.2011.01.012.
   PubMed Web of Science ®Google Scholar
• Schonthal AH. Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant glioma therapy. Anti-cancer agents medi chem. 2010;10:450–61. doi:10.2174/1871520611009060450.
   PubMed Web of Science ®Google Scholar
• Xia JJ, Pei LB, Zhuang JP, Ji Y, Xu GP, Zhang ZP, Li N, Yan JL. Celecoxib inhibits beta-catenin-dependent survival of the human osteosarcoma MG-63 cell line. J Int Med Res. 2010;38:1294–304. doi:10.1177/147323001003800411.
   PubMed Web of Science ®Google Scholar
• Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, Pals ST. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer. 2004;90:224–9. doi:10.1038/sj.bjc.6601505.
   PubMed Web of Science ®Google Scholar
• Poon R, Smits R, Li C, Jagmohan-Changur S, Kong M, Cheon S, Yu C, Fodde R, Alman BA. Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor). Oncogene. 2001;20:451–60. doi:10.1038/sj.onc.1204107.
   PubMed Web of Science ®Google Scholar
• Emori M, Kaya M, Mitsuhashi T, Asanuma H, Yamashita T. Desmoid tumor-associated pain is dependent on mast cell expression of cyclooxygenase-2. Diagn Pathol. 2014;9:14. doi:10.1186/1746-1596-9-14.
   PubMed Web of Science ®Google Scholar
• Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res. 2008;68:1213–20. doi:10.1158/0008-5472.CAN-07-5172.
   PubMed Web of Science ®Google Scholar
• Otero S, Moskovic EC, Strauss DC, Benson C, Miah AB, Thway K, Messiou C. Desmoid-type fibromatosis. Clin Radiol. 2015;70:1038–45. doi:10.1016/j.crad.2015.04.015.
   PubMed Web of Science ®Google Scholar
• Deyrup AT, Tretiakova M, Montag AG. Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer. 2006;106:208–13. doi:10.1002/cncr.21553.
   PubMed Web of Science ®Google Scholar
• Penel N, Le Cesne A, Bui BN, Perol D, Brain EG, Ray-Coquard I, Guillemet C, Chevreau C, Cupissol D, Chabaud S, et al. Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol: official journal of the European Society for Medical Oncology. 2011;22:452–7. doi:10.1093/annonc/mdq341.
   PubMed Web of Science ®Google Scholar
• Nishida Y, Tsukushi S, Shido Y, Wasa J, Ishiguro N, Yamada Y. Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2010;28:e107−9. doi:10.1200/JCO.2009.25.5950.
   PubMed Web of Science ®Google Scholar
• Wang YC, Wong JU. Complete remission of pancreatic head desmoid tumor treated by COX-2 inhibitor-a case report. World J Surg Oncol. 2016;14:190. doi:10.1186/s12957-016-0944-z.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Yoshikawa R, Yanagi H, Gega M, Fujiwara Y, Hashimoto-Tamaoki T, Hirota S, Tsujimura T, Tomita N. Regression of sporadic intra-abdominal desmoid tumour following administration of non-steroidal anti-inflammatory drug. World J Surg Oncol. 2008;6:17. doi:10.1186/1477-7819-6-17.
   PubMed Web of Science ®Google Scholar